{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:51:44Z","timestamp":1777679504340,"version":"3.51.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The prognosis of patients with metastatic renal cell carcinoma (RCC) has improved with the introduction of novel combination therapies, including monoclonal antibodies such as ipilimumab (against CTLA-4) with nivolumab (against PD-1). However, these checkpoint inhibitors are associated with a broad spectrum of immune-related adverse events (irAEs). Herein, we report a case of suspected immune-related cerebral vasculitis occurring three weeks after initiation of ipilimumab plus nivolumab in a patient with metastatic not-otherwise-specified (NOS) renal cell carcinoma (RCC). Brain MRI demonstrated multifocal supratentorial cortico-subcortical lesions with diffusion restriction and focal cortical enhancement, compatible with acute to subacute ischemia. In the context of the clinical presentation, exclusion of common stroke mechanisms, and a favorable response to corticosteroids, both clinically and para-clinically with a marked decline in CRP, the findings were considered most consistent with possible immune-related cerebral vasculitis. Three months after only one application of combined immunotherapy, a restaging CT scan showed an objective response in terms of partial remission. However, the metastatic RCC progressed after another 3 months, and the patient received two lines of tyrosine kinase inhibitors (sunitinib and cabozantinib). The patient died due to cancer progression, with an overall survival of 10.5 months. This case report provides experience with the management of possible immune-related cerebral vasculitis in patients with a rare malignancy. Severe cerebral vasculitis requires hospitalization with prompt diagnostic workup and immunosuppressive treatment. Despite the preterm permanent discontinuation of immunotherapy, the patients can benefit from the systemic treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1779015","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:34:03Z","timestamp":1774935243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report of cerebral vasculitis induced by ipilimumab with nivolumab in a patient with metastatic renal cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Patrik","family":"Palacka","sequence":"first","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]},{"name":"Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"M\u00e1lek","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute","place":["Bratislava, Slovakia"]},{"name":"Department of Urology, University Hospital","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Makovn\u00edk","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e1ta","family":"Felediov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Rychl\u00fd","sequence":"additional","affiliation":[{"name":"Department of Pathology, Unilabs","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg\u00edna","family":"Koln\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal\u00a0cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23.e9","DOI":"10.1016\/j.urolonc.2012.08.011","article-title":"Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program","volume":"32","author":"Shuch","year":"2014","journal-title":"Urol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer\u2014Results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: A review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0828-7","article-title":"Systemic vasculitis associated with immune check point inhibition: analysis and review","volume":"21","author":"Crout","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: A systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101845","article-title":"Classification and epidemiology of vasculitis: Emerging\u00a0concepts","volume":"37","author":"Ecclestone","year":"2023","journal-title":"Best Pr Res Clin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejro.2022.100434","article-title":"Imaging features of toxicities associated with immune checkpoint inhibitors","volume":"9","author":"Gosangi","year":"2022","journal-title":"Eur J Radiol Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A4893","article-title":"Intracranial vessel wall MRI: principles and expert consensus recommendations of the american society of neuroradiology","volume":"38","author":"Mandell","year":"2017","journal-title":"Am J Neuroradiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.2249","article-title":"MRI of cerebral microhemorrhages","volume":"189","author":"Blitstein","year":"2007","journal-title":"Am J Roentgenol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102714","article-title":"Primary CNS vasculitis: A systematic review on clinical characteristics associated with abnormal biopsy and angiography","volume":"20","author":"Krawczyk","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01375-5","article-title":"Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: A case report","volume":"21","author":"Harada","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S343876","article-title":"A case of igA vasculitis during nivolumab therapy for renal cell carcinoma","volume":"14","author":"Nagaoka-Takatori","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.46883\/2022.25920957","article-title":"Leukocytoclastic vasculitis induced by immune checkpoint inhibition in a patient with advanced renal cell carcinoma","volume":"36","author":"Panian","year":"2022","journal-title":"Oncol Williston Park"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108265","article-title":"Immune checkpoint inhibitor-related CNS vasculitis\u2014A systematic review and report of 6 cases","volume":"34","author":"Erritz\u00f8e-Jervild","year":"2025","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management\u00a0of\u00a0toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B22","unstructured":"Nucala\u2014Mepolizumab"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1779015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:34:04Z","timestamp":1774935244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1779015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1779015"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1779015","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1779015"}}